Australian pharma giant CSL announced a comprehensive restructuring plan involving the separation of its vaccine subsidiary Seqirus as an independent publicly listed company by mid-2026, alongside workforce reductions up to 15%. Despite a modest 2% revenue increase in the vaccine unit, CSL cites competitive pressures and market complexities driving cost-saving measures to enhance pipeline productivity and profitability. The restructuring emphasizes a strategic pivot to prioritize core assets and streamline R&D operations.